Exelixis (EXEL) announced that the company has entered into a clinical development collaboration with Merck (MRK), known as MSD outside of the United States and Canada, to supply Keytrude Qlex injection for subcutaneous administration in combination with zanzalintinib in Stellar-316, a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer, CRC. Under the terms of the clinical development collaboration with Merck, Exelixis is sponsoring the Stellar-316 pivotal trial, and Merck will supply Keytrude Qlex.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion
- Exelixis price target raised to $56 from $54 at H.C. Wainwright
- Exelixis price target raised to $50 from $49 at Morgan Stanley
- Exelixis price target raised to $47 from $44 at Stifel
- Exelixis price target raised to $55 from $51 at TD Cowen